More

    Fourth NDA for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-™T) Accepted by the Center for Drug Evaluation



    [
    Fourth NDA for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-™T) Accepted by the Center for Drug Evaluation
    [og_img]
    https://www.investing.com/news/press-releases/fourth-nda-for-kelunbiotechs-trop2-adc-sacituzumab-tirumotecan-sact-accepted-by-the-center-for-drug-evaluation-93CH-4058561


    Investing.com

    Latest articles

    spot_imgspot_img

    Related articles

    spot_imgspot_img